Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

已完结 10 由静静发布于 2026/5/28 9:45:25

DOI:10.1016/S1470-2045(12)70477-1
作者：Jaafar Bennouna, Javier Sastre, Dirk Arnold, Pia ?sterlund, Richard Greil, Eric Van Cutsem, Roger von Moos, Jose Maria Viéitez, Olivier Bouché, Christoph
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1016/S1470-2045(12)70477-1

Elsevier

Abstract：Background: Bevacizumab plus fluoropyrimidine-based chemotherapy is standard treatment for first-line and bevacizumab-naive second-line metastatic colorectal cancer. We assessed continued us

应助信息

19小时前

离异带俩喷火龙王

f6b82ee25a3711f1b78934735aa3bc31.pdf 已采纳

20小时前

Book学术机器人

2026/5/28 9:45:25 未找到该文献，机器人已退出，请等待人工下载

2026/5/28 9:45:25 Book学术AI机器人收到请求，开始寻找文献

2026/5/28 9:45:25 已向机器人发送请求

20小时前

静静发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Chemical Society (ACS)Grain Boundary Softening: A Potential Mechanism for Lithium Metal Penetration through Stiff Solid Electrolytes